Theravance Biopharma reports positive data from trials conducted on VIBATIV
US-based biopharmaceutical company Theravance has reported positive results from trials of VIBATIV (telavancin) in treating osteomyelitis and combat methicillin-resistant staphylococcus aureus (MRSA) pathogens.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Infectious Diseases | MRSA | Osteomyelitis | Pharmaceuticals | Staphylococcus Aureus | Superbugs